Manufacturing Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Pharmaceutical TechnologyManufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trialNext: FDA weighs drug repurposing pathway for underserved diseases Related Stories Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026
